Evidence map›Paper›PMID 38315015›Full record

ArticleJournal of virology2024

Class A capsid assembly modulator apoptotic elimination of hepatocytes with high HBV core antigen level

Jan Martin Berke, Ying Tan, Sarah Sauviller, Dai-Tze Wu, Ke Zhang, Nádia Conceição-Neto, Alfonso Blázquez Moreno, Desheng Kong, George Kukolj, Chris Li and 3 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. CAM-A-dependent HBV core aggregation induces apoptosis through ANXA1.JHEP reports : innovation in hepatology · 2024
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Jan Martin BerkeInfectious Diseases Discovery, Infectious Diseases and Vaccines, Janssen Research and Development, Turnhoutseweg, Beerse, Belgium.
Ying TanInfectious Diseases Discovery, Janssen Research and Development, Jinchuang Mansion, Pudong, Shanghai, China.
Sarah SauvillerInfectious Diseases Discovery, Infectious Diseases and Vaccines, Janssen Research and Development, Turnhoutseweg, Beerse, Belgium.ORCID 0009-0003-5856-6269
Dai-Tze WuInfectious Diseases Discovery, Janssen Research and Development, Jinchuang Mansion, Pudong, Shanghai, China.
Ke ZhangInfectious Diseases Discovery, Janssen Research and Development, Jinchuang Mansion, Pudong, Shanghai, China.
Nádia Conceição-NetoInfectious Diseases Discovery, Infectious Diseases and Vaccines, Janssen Research and Development, Turnhoutseweg, Beerse, Belgium.
Alfonso Blázquez MorenoInfectious Diseases Biomarkers, Infectious Diseases and Vaccines, Janssen Research and Development, Turnhoutseweg, Beerse, Belgium.
Desheng KongInfectious Diseases Discovery, Janssen Research and Development, Jinchuang Mansion, Pudong, Shanghai, China.
George KukoljInfectious Diseases Discovery, Janssen Research and Development, Brisbane, California, USA.
Chris LiInfectious Diseases Discovery, Janssen Research and Development, Brisbane, California, USA.
Ren ZhuInfectious Diseases Discovery, Janssen Research and Development, Jinchuang Mansion, Pudong, Shanghai, China.
Isabel NájeraInfectious Diseases Discovery, Janssen Research and Development, Brisbane, California, USA.
Frederik PauwelsInfectious Diseases Discovery, Infectious Diseases and Vaccines, Janssen Research and Development, Turnhoutseweg, Beerse, Belgium.
Janssen (Belgium) · BEJinchuan (China) · CNJanssen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Capsid assembly is critical in the hepatitis B virus (HBV) life cycle, mediated by the viral core protein. Capsid assembly is the target for new anti-viral therapeutics known as capsid assembly modulators (CAMs) of which the CAM-aberrant (CAM-A) class induces aberrant shaped core protein structures and leads to hepatocyte cell death. This study aimed to identify the mechanism of action of CAM-A modulators leading to HBV-infected hepatocyte elimination where CAM-A-mediated hepatitis B surface antigen (HBsAg) reduction was evaluated in a stable HBV replicating cell line and in AAV-HBV-transduced C57BL/6, C57BL/6 SCID, and HBV-infected chimeric mice with humanized livers. Results showed that IMPORTANCE: Treatment with hepatitis B virus (HBV) capsid assembly modulators that induce the formation of aberrant HBV core protein structures (CAM-A) leads to programmed cell death, apoptosis, of HBV-infected hepatocytes and subsequent reduction of HBV antigens, which differentiates CAM-A from other CAMs. The effect is dependent on the

Indexed as

Antiviral AgentsApoptosisGene Expression Regulation, ViralHepatitis B Core AntigensHepatitis B virusHepatocytesProtein BiosynthesisAnimalsAntigen PresentationCapsidCapsid ProteinsCD8-Positive T-LymphocytesCell LineHepatitis BHepatitis B e AntigensHepatitis B Surface AntigensAntiviral AgentsCapsid ProteinsHepatitis B Core AntigensHepatitis B e AntigensHepatitis B Surface Antigensapoptosiscapsid assembly modulatorhepatitis B virusproliferationtransduced and chimeric mice

Identifiers

PMID38315015
PMCPMC10949496
OpenAlexW4391531780

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.